Pinehurst Unveils Course No. 11 As Golf's Biggest Resort Grows Again
The biggest golf resort in the U.S. is growing yet again, with the iconic Pinehurst Resort in the sand hills of North Carolina unveiling plans for its 11th 18-hole course.
Designed by the accomplished team of Bill Coore and Ben Crenshaw, Pinehurst No. 11 will sit adjacent to Pinehurst No. 10, which debuted last year on the site of a former sand mine that sat unused for more than a decade. Construction will begin later this year, with No. 11 expected to open for play in Fall of 2027.
'I don't think I have ever seen two more physically different sites that are contiguous, literally touching each other than the sites for No. 10 and No. 11,' said Coore, who grew up in North Carolina and has been playing courses in the Pinehurst area since his youth. 'They're monumentally different in terms of their character. And the two courses will (also) be massively different in terms of their characteristics, just because of the landforms.'
The routing for the new course is situated at Pinehurst Sandmines, a 900-acre property that Pinehurst President Tom Pashley has called the resort's 'Field of Dreams' – an area that could realize the evolving demands of destination golf in a modern way. Once Tom Doak and Angela Moser were enlisted to build No. 10 on the site, expectations were that it would eventually include two championship courses, a short course, a putting course, a new clubhouse, pro shop, and golf lodging for guests.
Designed by Tom Doak and Angela Moser, Pinehurst No. 10 opened in 2024 on a 900-acre property that ... More was acquired by the resort in 2011.
After sitting on the land from 2011 to 2023, the opportunity is ripe for Pinehurst to pursue continued growth. There have not only been a record number of rounds of golf played in recent years, but the number of U.S. golf travelers has topped 12 million in each of the past three years, the highest levels on record, according to the National Golf Foundation.
Coore and Crenshaw, who were responsible for the major restoration of Pinehurst's flagship No. 2 course in 2011, had done a routing in 2012 for a course on the property that is now Sandmines.
But Pashley has said he's grateful it wasn't pursued at the time because the resort has learned much more about the look and feel of the 'future of golf.'
After the restoration of No. 2, Pinehurst introduced its nearly two-acre Thistle Dhu putting course in 2012 and opened its hugely popular Cradle par-3 course just outside the main clubhouse in 2017. Architect Gil Hanse, who built the Cradle, was celebrated in 2018 for his redesign of Pinehurst No. 4. Pinehurst No. 8 also underwent a facelift, but the construction of No. 10 – along with the branding of Pinehurst Sandmines – represented the resort's first new 18-hole course project in nearly three decades.
Pinehurst No. 10 has the Sandmines logo.
While No. 11 will sit next to its predecessor, the terrain for the two courses is very different. As a result, the designs will complement each other by contrasting with one another.
'The two courses really couldn't be more different, and we love that,' says Pashley. 'Golf in the North Carolina Sandhills can be an experience unlike any other, and we believe the golf at Pinehurst Sandmines will be a great representation of that.'
While Pinehurst No. 10 has elevation changes and expansive vistas that are noteworthy for the area, No. 11 will play over and around jutting ridges and massive mounds of material left over from long-time mining operations. The dunes aren't natural, but these so-called spoils are deposits left by miners who decades ago were stripping sand and other material.
'We expected sand here,' said Coore. 'What we didn't expect were these created landforms that have now matured into a very natural appearance and condition. We have sand, interesting landforms, (and) trees. It's pretty good.'
Bill Coore on the site that will be home to Pinehurst No. 11.
Coore says there's a more intimate scale to the land, which he describes with terms like quirky, choppy and ridgey.
'You're winding your way through trees and over old piles and across ridges," added Coore. "We're far, far from the sea, but we have these contours and features and landforms that remind you of spots in Ireland or Scotland. And yet here it is, in Pinehurst.'
As far as Pinehurst's continued growth, the 6,000-square-foot pro shop and locker room for Sandmines will open this June, with a restaurant and bar to follow in August.
Plans for guests to stay on the property, which is about four miles south of the resort's main clubhouse, are ongoing and could be in place by the end of 2027.
Aerial of the 17th hole at Pinehurst No. 11, which breaks ground on construction later in 2025.
'We want Pinehurst Sandmines to be a special place not just in Pinehurst, but in the game of golf that will stand the test of time and enhance the soul of American golf,' says Bob Dedman Jr., the owner and CEO of Pinehurst Resort.
'The vision Coore and Crenshaw have for No. 11 coupled with what Tom Doak has already done at No. 10 makes that hope more of a possibility, and we couldn't be more excited about what the future has in store.'
When No. 11 opens, it will give Pinehurst 207 holes in total, further solidifying the resort's standing as the largest in the world of destination golf. The only other public resorts with more than 100 holes are Reynolds Lake Oconee in Georgia (126), Bandon Dunes in Oregon (122) and Gull Lake View in Michigan (108).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
10 hours ago
- Business Insider
Savara publishes IMPALA-2 clinical trial results in NEJM
Savara (SVRA) announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript will appear in the online version of the publication. Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the company's corporate website. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Wire
16 hours ago
- Business Wire
New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled 'A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis' Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the Company's corporate website. 'IMPALA-2, the largest and longest Phase 3 clinical trial conducted in patients with autoimmune PAP, demonstrated that 48 weeks of once daily administration of inhaled molgramostim addresses the underlying pathophysiology of this chronic rare lung disease,' said Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine and Lead Clinical Investigator of the IMPALA-2 trial. 'Treatment with molgramostim improved the cardinal manifestations of autoimmune PAP, namely it reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. Additionally, molgramostim was well tolerated with no notable safety concerns.' IMPALA-2 achieved statistical significance on its primary endpoint, change from baseline in the hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%) at Week 24. Molgramostim significantly improved pulmonary gas transfer as measured by DLco% at Week 24 compared with placebo (9.8% vs. 3.8%; estimated treatment difference, 6.0%; P<0.001 by comparison of least-squares means [LSMs]). The beneficial effect of molgramostim on pulmonary gas transfer was maintained to Week 48 as shown by the difference in LSM change from baseline in DLco% at Week 48 between molgramostim and placebo groups (11.6% vs. 4.7%; estimated treatment difference, 6.9%; P<0.001). The mean improvements in DLco% from baseline for molgramostim (9.8% at Week 24 and 11.6% at Week 48) are similar to the minimal clinically meaningful difference (MCID) in DLco% of 10% reported for pulmonary fibrosis. 1 Molgramostim improved respiratory health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) Total and Activity scores. The magnitude of LSM reduction from baseline in SGRQ Total score was significantly greater in the molgramostim group than placebo at Week 24 (-11.5 points vs. -4.9 points, estimated difference, -6.6 points; P=0.007) and remained numerically greater at Week 48 (-10.7 points vs. -5.9 points, estimated difference, -4.9 points [95% confidence interval, -10.8, 1.0]). The LSM change from baseline in SGRQ Activity score was greater for molgramostim compared with placebo at Week 24 (-13.0 points vs. -5.2 points, estimated difference, -7.8 points [95% confidence interval, -14.1, -1.5]) and at Week 48 (-13.4 vs. -7.4 points, estimated difference, -6.0 points [95% confidence interval, -13.6, 1.6]). Molgramostim improved patient function as measured by exercise capacity (expressed as peak metabolic equivalents [METs]). A MET is a unit of resting oxygen uptake which measures energy expenditure. The LSM change from baseline in peak-METs was greater at Week 48 for molgramostim than placebo (1.1 vs. 0.6; estimated treatment difference, 0.6; [95% confidence interval, 0.1, 1.0]). Peak-METs is a clinically useful unit of measure reflecting exercise capacity, prognosis, and mortality in cardiovascular disease for which a 0.5-MET increase comprises a clinically useful measure of rehabilitation. 2 Using the treadmill test in IMPALA-2, the LSM change in peak-METs from baseline to Week 48 was 1.1 in molgramostim-treated patients and the between-group difference observed at Week 48 was 0.6 peak-METs. Molgramostim reduced surfactant burden as measured by ground glass opacity (GGO) score, an exploratory endpoint in IMPALA-2; GGO scores were determined by two blinded radiologists from a chest CT scan, with scores ranging from 0 to 15 (higher scores are worse). The mean reduction from baseline in GGO score was greater in the molgramostim group than the placebo group at Week 24 (-2.1 vs -1.1). Further, the number of patients who received ≥1 whole lung lavage as rescue therapy during the double-blind intervention period was lower with molgramostim than placebo (6 [7%] vs. 11 [13%]). In IMPALA-2, molgramostim was well tolerated. Most treatment-emergent adverse events (AEs) were mild or moderate, and few led to discontinuation, with 98% of patients in the molgramostim group and 96% of patients in the placebo group completing the 48-week double-blind period on treatment. About IMPALA-2 IMPALA-2 was a global, pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the efficacy and safety of molgramostim 300 mcg self-administered once daily by inhalation with matching placebo in patients with autoimmune PAP. The trial was conducted at 43 clinical trial sites across 16 countries, including the U.S., Canada, Japan, South Korea, Australia, and countries in Europe, including Turkey. The primary efficacy assessment was hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%), a gas transfer measure, and the primary endpoint was change from baseline to Week 24 in percent predicted DLco%, with a secondary endpoint of change from baseline to Week 48 in percent predicted DLco%. Three additional secondary efficacy variables evaluated clinical measures of patient benefit: St. George's Respiratory Questionnaire (SGRQ) Total score, SGRQ Activity score, and exercise capacity using a treadmill test, with each endpoint measured at Weeks 24 and 48. The primary time point for efficacy assessments was at Week 24; however, efficacy was assessed through Week 48 to evaluate durability of effect. Safety was assessed through Week 48. All patients who completed the 48-week double-blind treatment period continued into a 96-week open-label period during which molgramostim 300 mcg is administered once daily. Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn. 1 Raghu G, et al. Am J Respir Crit Care Med 2022;205:e18-e47. 2 Ross R, et al. Circulation 2016;134:e653-e99; Grace SL, et al. Can J Cardiol 2014;30:945-8; Kehler DS, et al. J Cardiopulm Rehabil Prev 2017;37:250-6.
Business Wire
a day ago
- Business Wire
SiriusXM's SXM-10 Satellite Successfully Begins Operational Service
NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--SiriusXM and Maxar Space Systems announced today that the SXM-10 satellite has completed in-orbit testing and is now fully operational by SiriusXM following its successful launch by a SpaceX Falcon 9 rocket on June 7, 2025. SXM-10 will provide continuous reliable delivery of SiriusXM's audio entertainment and information services to consumers. SXM-10 is the 11th high-powered, digital audio radio satellite built by Maxar Space Systems on the Maxar 1300™ platform. Share 'The SXM-10 satellite strengthens the health of our fleet and the infrastructure that provides a critical foundation for our audio entertainment and information services enjoyed by tens of millions of people across North America,' said Bridget Neville, SiriusXM's Senior Vice President & GM of Signal Distribution Engineering. 'The successful launch and handover of SXM-10 marks another milestone in our long-standing partnership with SiriusXM,' said Chris Johnson, CEO of Maxar Space Systems. 'This satellite reflects our shared commitment to innovation and reliability, and we are proud to be able to leverage our proven Maxar 1300™ platform to help SiriusXM deliver advanced audio entertainment services to millions of listeners.' SXM-10 will help provide continuous reliable delivery of SiriusXM's audio entertainment and information services to consumers. SXM-10 is the 11 th high-powered, digital audio radio satellite built by Maxar Space Systems for SiriusXM and is built on the Maxar 1300™ platform. SXM-10 is more than 27 feet tall and over 100 feet long with its solar arrays deployed, and weighed almost 6,600 kg at launch. SXM-10 features a large unfurlable S-band reflector antenna supplied by L3Harris that enables SiriusXM programming to reach approximately 175 million SiriusXM-equipped vehicles on the road today. SXM-10 is the second new satellite to commence service for SiriusXM in 2025 after SXM-9 began service in January. SiriusXM and Maxar Space Systems previously announced that Maxar Space has also been commissioned to build the SXM-11 and -12 satellites for SiriusXM, and those programs are ongoing with launches expected in 2026 and 2027, respectively. About Sirius XM Holdings Inc. SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; an expansive podcast network; and a suite of business and advertising solutions. Reaching a combined monthly audience of approximately 160 million listeners, SiriusXM offers a broad range of content for listeners everywhere they tune in with a diverse mix of live, on-demand, and curated programming across music, talk, news, and sports. For more about SiriusXM, please go to: About Maxar Space Systems Maxar Space Systems is a leading satellite manufacturer and provider of advanced solutions for space exploration. We deliver innovative solutions to commercial and government customers helping them unlock the promise of space to solve problems on Earth and beyond. We address a broad spectrum of needs for our customers, including mission systems engineering, product design, spacecraft manufacturing, assembly, integration and testing. Maxar Space Systems is a trusted partner in commercial and government missions, combining more than 65 years of deep mission understanding and industry leading performance. For more information, visit This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our outlook and our future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning or the negative version of such these words or phrases. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. The following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: Risks Relating to our Business and Operations: We face substantial competition and that competition has increased over time; our SiriusXM service has suffered a loss of subscribers and our Pandora ad-supported service has similarly experienced a loss of monthly active users; if our efforts to attract and retain subscribers and listeners, or convert listeners into subscribers, are not successful, our business will be adversely affected; we engage in extensive marketing efforts and the continued effectiveness of those efforts is an important part of our business; we rely on third parties for the operation of our business, and the failure of third parties to perform could adversely affect our business; failure to successfully monetize and generate revenues from podcasts and other non-music content could adversely affect our business, operating results, and financial condition; we may not realize the benefits of acquisitions or other strategic investments and initiatives; and the impact of economic conditions may adversely affect our business, operating results, and financial condition. Risks Relating to our SiriusXM Business: Changing consumer behavior and new technologies relating to our satellite radio business may reduce our subscribers and may cause our subscribers to purchase fewer services from us or to cancel our services altogether, resulting in less revenue to us; a substantial number of our SiriusXM service subscribers periodically cancel their subscriptions and we cannot predict how successful we will be at retaining customers; our ability to profitably attract and retain subscribers to our SiriusXM service is uncertain; our business depends in part upon the auto industry; the imposition of tariffs by the United States government could have a major effect on the United States auto industry, which Sirius XM is dependent upon as a material source of new subscribers; failure of our satellites would significantly damage our business; and our SiriusXM service may experience harmful interference from wireless operations. Risks Relating to our Pandora and Off-platform Business: Our Pandora and Off-platform business generates a significant portion of its revenues from advertising, and reduced spending by advertisers could harm our business; emerging industry trends may adversely impact our ability to generate revenue from advertising; our failure to convince advertisers of the benefits of our Pandora ad-supported service could harm our business; if we are unable to maintain our advertising revenue our results of operations will be adversely affected; changes to mobile operating systems and browsers may hinder our ability to sell advertising and market our services; and if we fail to accurately predict and play music, comedy or other content that our Pandora listeners enjoy, we may fail to retain existing and attract new listeners. Risks Relating to Laws and Governmental Regulations: Privacy and data security laws and regulations may hinder our ability to market our services, sell advertising and impose legal liabilities; consumer protection laws and our failure to comply with them could damage our business; failure to comply with FCC requirements could damage our business; we may face lawsuits, incur liability or suffer reputational harm as a result of content published or made available through our services; and environmental, social and governance expectations and related reporting obligations may expose us to potential liabilities, increased costs, reputational harm, and other adverse effects. Risks Associated with Data and Cybersecurity and the Protection of Consumer Information: If we fail to protect the security of personal information about our customers, we could be subject to costly government enforcement actions and private litigation and our reputation could suffer; we use artificial intelligence in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability and adversely affect our results of operations; and interruption or failure of our information technology and communications systems could impair the delivery of our service and harm our business. Risks Associated with Certain Intellectual Property Rights: Rapid technological and industry changes and new entrants could adversely impact our services; the market for music rights is changing and is subject to significant uncertainties; our Pandora services depend upon maintaining complex licenses with copyright owners, and these licenses contain onerous terms; failure to protect our intellectual property or actions by third parties to enforce their intellectual property rights could substantially harm our business and operating results; and some of our services and technologies use 'open source' software, which may restrict how we use or distribute our services or require that we release the source code subject to those licenses. Risks Related to our Capital Structure: While we currently pay a quarterly cash dividend to holders of our common stock, we may change our dividend policy at any time; our holding company structure could restrict access to funds of our subsidiaries that may be needed to pay third party obligations; we have significant indebtedness, and our subsidiaries' debt contains certain covenants that restrict their operations; and our ability to incur additional indebtedness to fund our operations could be limited, which could negatively impact our operations. Risks Related to the Transactions: We may have a significant indemnity obligation to Liberty Media, which is not limited in amount or subject to any cap, if the transactions associated with the Split-Off are treated as a taxable transaction; we may determine to forgo certain transactions that might otherwise be advantageous in order to avoid the risk of incurring significant tax-related liabilities; we have assumed and are responsible for all of the liabilities attributed to the Liberty SiriusXM Group as a result of the completion of the Transactions, and acquired the assets of SplitCo on an 'as is, where is' basis; we may be harmed by securities class action and derivative lawsuits in connection with the Transactions; it may be difficult for a third party to acquire us, even if doing so may be beneficial to our stockholders; we have directors associated with Liberty Media, which may lead to conflicting interests; and our directors and officers are protected from liability for a broad range of actions. Other Operational Risks: If we are unable to attract and retain qualified personnel, our business could be harmed; our facilities could be damaged by natural catastrophes or terrorist activities; the unfavorable outcome of pending or future litigation could have an adverse impact on our operations and financial condition; we may be exposed to liabilities that other entertainment service providers would not customarily be subject to; and our business and prospects depend on the strength of our brands. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, which is filed with the Securities and Exchange Commission (the "SEC") and available at the SEC's Internet site ( The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.
